People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Otonomy, Inc. | — | Biotechnology | Series B | $44.8M | $961.1M | 2010 |
| JumpCode Genomics, Inc. | — | Biotechnology | Series B | $38.7M | $23.4M | 2023 |
| Synthorx, Inc. | — | Biotechnology | Series B | $34.7M | $1.1B | 2014 |
| Onchilles Pharma, Inc. | — | Biotechnology | Seed | $3.6M | $158.5M | 2020 |
| Afraxis, Inc. | — | Biotechnology | Seed | $2.9M | $13.3M | 2009 |
| Cellular Approaches, Inc. | — | Biotechnology | Seed | $2.6M | $113.7M | 2016 |
Court Turner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Court Turner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jay Lichter | 3 | 7 |
| Tighe Reardon | 2 | 7 |
| Douglas Downs | 2 | 6 |
| ANDREW LEVIN | 1 | 17 |
| Peter Thompson | 1 | 16 |
| Peter Bisgaard | 1 | 9 |
| Eugene Chen | 1 | 9 |
| Michael Liang | 1 | 9 |
| Jeffrey Harris | 1 | 9 |
| Keith Brown | 1 | 8 |
| David Weber | 1 | 8 |
| Brian Dovey | 1 | 7 |
| Heather Preston | 1 | 6 |
| Laura Shawver | 1 | 6 |
| John McKearn | 1 | 6 |
| Jay Lichter, Ph.D. | 1 | 5 |
| Dan Kidle | 1 | 4 |
| Kevin Li | 1 | 4 |
| Frank Witney | 1 | 3 |
| Jay B. Lichter | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.